<DOC>
	<DOCNO>NCT00055731</DOCNO>
	<brief_summary>RATIONALE : Androgens stimulate growth prostate cancer cell . Drugs nilutamide , bicalutamide , flutamide , cyproterone may stop adrenal gland produce androgen . Drugs use chemotherapy use different way stop tumor cell divide stop grow die . It yet know whether hormone therapy effective without chemotherapy treat prostate cancer . PURPOSE : Randomized phase III trial compare effectiveness hormone therapy without docetaxel estramustine treat patient prostate cancer locally advance high risk relapse .</brief_summary>
	<brief_title>Hormone Therapy With Without Docetaxel And Estramustine Treating Patients With Prostate Cancer That Locally Advanced At High Risk Relapse</brief_title>
	<detailed_description>OBJECTIVES : - Compare 8-year survival rate , term clinical biological remission , patient locally advanced prostate cancer high risk relapse treat neoadjuvant release factor agonist therapy antiandrogen therapy without docetaxel estramustine give local radiotherapy prostatectomy . - Compare prostate-specific antigen level 3 month patient treat regimen . - Compare cancer progression ultrasound patient treat regimen . - Compare survival without clinical remission patient treat regimen . - Compare overall survival patient treat regimen . - Compare toxicity regimens patient . - Compare quality life patient treat regimen . OUTLINE : This randomize , multicenter study . Patients stratify accord Gleason score ( 7 vs 7 ) , T stage ( T1 T2 v T3 T4 ) , prostate-specific antigen level ( 20 ng/mL less vs great 20 ng/mL ) , lymph node involvement ( N0 vs N1 N2 ) . Patients randomize 1 2 treatment arm . - Arm I : Patients receive oral antiandrogen therapy comprise nilutamide twice daily bicalutamide daily flutamide 3 time daily cyproterone 4 time daily . Patients also receive docetaxel IV 1 hour day 2 estramustine day 1-5 . Treatment repeat every 21 day total 4 course . Patients also receive luteinizing hormone-releasing hormone ( LHRH ) therapy IV comprise buserelin subcutaneously ( SC ) every 2 month triptorelin , leuprolide , goserelin SC every 3 month . - Arm II : Patients receive antiandrogen LHRH therapy arm I . Beginning approximately 21 day chemotherapy complete , patient N0 disease undergo radiotherapy 5 day week 6-7 week radical prostatectomy . Patients N1 N2 disease undergo radiotherapy local treatment . Hormonal therapy continue arm 3 year absence disease progression unacceptable toxicity . Quality life assess baseline , 3 month , 1 year . Patients follow every 6 month 5 year . PROJECTED ACCRUAL : A total 250 patient ( 125 per treatment arm ) accrue study within 3 year .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Bicalutamide</mesh_term>
	<mesh_term>Nilutamide</mesh_term>
	<mesh_term>Leuprolide</mesh_term>
	<mesh_term>Triptorelin Pamoate</mesh_term>
	<mesh_term>Goserelin</mesh_term>
	<mesh_term>Cyproterone Acetate</mesh_term>
	<mesh_term>Flutamide</mesh_term>
	<mesh_term>Estramustine</mesh_term>
	<mesh_term>Buserelin</mesh_term>
	<mesh_term>Cyproterone</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma prostate Locally advance disease high risk relapse No clinically radiologically suspected metastasis Prior lymphadenectomy require Meets least 1 follow criterion poor prognosis : Gleason score great 7 T3 T4 disease Prostatespecific antigen great 20 ng/mL N1 disease PATIENT CHARACTERISTICS : Age Under 80 Performance status ECOG 02 Life expectancy More 10 year Hematopoietic Absolute neutrophil count great 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic AST ALT great 1.5 time upper limit normal ( ULN ) Bilirubin great ULN Renal Creatinine le 1.6 mg/dL OR Creatinine clearance great 60 mL/min Cardiovascular No uncontrolled severe cardiovascular disease No prior thrombosis Pulmonary No prior pulmonary embolus Other No active infection No intolerance aspirin No prior malignancy except basal cell skin cancer No physical psychological condition would preclude study compliance PRIOR CONCURRENT THERAPY : Biologic therapy No concurrent immunotherapy Chemotherapy No prior chemotherapy No concurrent chemotherapy Endocrine therapy No prior hormonal therapy No concurrent hormonal therapy Radiotherapy Not specify Surgery See Disease Characteristics Other No concurrent anticancer therapy</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>April 2008</verification_date>
	<keyword>stage III prostate cancer</keyword>
	<keyword>stage IIB prostate cancer</keyword>
	<keyword>stage IIA prostate cancer</keyword>
</DOC>